Study on efficacy of Adefovirdipivoxil therapy for patients with chronic hepatitis B resistant to Lamivudine

Objective To observe the efficacy and safety of Adefovirdipivoxil therapy for patients with chronic hepatitis B resistant to Lamivudine. Methods Randomized,doubleblind,Lamivudine controlled study was conducted in 56 chronic hepatitis B patients. Eligible patients stopped lamivudine therapy and were assigned to receive 10 mg of Adefovirdipivoxil once daily or 100 mg of Lamivudine once daily for 6 months. Serum HBV DNA,hepatitis B serology markers and ALT level,were measured at regular intervals,the adverse events were recorded at the same time. Results Serum HBV DNA levels of 25 patients(89.3%)who received Adefovirdipivoxil decreased after 6 months,and normalization of ALT levels in patients who received Adefovirdipivoxil was 100%,which was greater than that with Lamivudine. There was no significant statistical difference in HBeAg sero conversion rate between the two groups (P =0.237). There was no teratogenicity of therapy with Adefovirdipivoxil and Lamivudine in 6 months. Conclusion Adefovirdipivoxil is safe and efficacious for Lamivudine-resistant patients with chronic hepatitis B.